Xvivo Perfusion AB (publ)
XVIPY · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $8,916 | $9,812 | $14,902 | $15,970 |
| - Cash | $323 | $316 | $416 | $450 |
| + Debt | $111 | $29 | $34 | $10 |
| Enterprise Value | $8,704 | $9,525 | $14,521 | $15,530 |
| Revenue | $178 | $219 | $228 | $198 |
| % Growth | -18.4% | -3.9% | 14.7% | – |
| Gross Profit | $133 | $160 | $175 | $148 |
| % Margin | 74.4% | 73.4% | 77% | 74.5% |
| EBITDA | $16 | $38 | $28 | $20 |
| % Margin | 9% | 17.3% | 12.3% | 10.3% |
| Net Income | $2 | -$12 | $36 | $86 |
| % Margin | 0.9% | -5.7% | 16% | 43.2% |
| EPS Diluted | 0.013 | -0.098 | 0.29 | 0.68 |
| % Growth | 112.8% | -133.6% | -57.4% | – |
| Operating Cash Flow | $9 | -$15 | $62 | $23 |
| Capital Expenditures | -$36 | -$18 | -$22 | $0 |
| Free Cash Flow | -$27 | -$33 | $40 | $23 |